All In Biotech

Drug Trial Radar · NCT03564340

Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

A Phase 1/2 Study of REGN4018 (Ubamatamab), a MUC16×CD3 Bispecific Antibody, Administered Alone or in Combination With Cemiplimab in Patients With Recurrent Ovarian Cancer or Other Recurrent MUC16+ Cancers

Last checked: Nov 20, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

890

Planned (sponsor's estimate)

Start

May 21, 2018

Primary completion

May 10, 2027

Study completion May 10, 2027

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Jun 20, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to: * Learn about the safety of ubamatamab and to find out what dose of ubamatamab can be given alone or with cemiplimab to patients with ovarian cancer or cancer of the uterus * The study will also look at the levels of ubamatamab and/or cemiplimab in the body and measure how well the body can remove the study drug(s). This is called pharmacokinetics * The study will also look at any signs that ubamatamab alone or with cemiplimab can treat recurrent advanced ovarian cancer or cancer of the uterus * To find out how safe and tolerable pretreatment is in combination with ubamatamab and to see how well it works to prevent or minimize Cytokine Release Syndrome (CRS)

Conditions

  • Recurrent Ovarian Cancer
  • Recurrent Fallopian Tube Cancer
  • Recurrent Primary Peritoneal Cancer
  • Recurrent Endometrial Cancer
  • Endometrial Cancer
  • Low-grade Serous Ovarian Cancer

Interventions

  • UbamatamabDrug

    Administered per the protocol

  • CemiplimabDrug

    Administered per the protocol

  • SarilumabDrug

    Administered per the protocol

  • TocilizumabDrug

    Administered per the protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with Dose-limiting toxicity (DLTs) for ubamatamab monotherapyTime frame: From Cycle 1, Day 1 up to 35 days
  2. Number of participants with DLTs for ubamatamab with cemiplimabTime frame: From Cycle 2, Day 1 up to 21 days
  3. Number of participants with Treatment-emergent adverse event (TEAE)s (including immune-related adverse events (imAEs)) for ubamatamab monotherapyTime frame: Up to 2 years
  4. Number of participants with TEAEs (including imAEs) for ubamatamab with cemiplimabTime frame: Up to 2 years
  5. Number of participants with serious adverse events (SAEs) for ubamatamab monotherapyTime frame: Up to 2 years
  6. Number of participants with SAEs for ubamatamab with cemiplimabTime frame: Up to 2 years
  7. Number of deaths for ubamatamab monotherapyTime frame: Up to 2 years
  8. Number of deaths for ubamatamab with cemiplimabTime frame: Up to 2 years
  9. Number of participants with laboratory abnormalities (grade 3 or higher per Common Terminology Criteria for Adverse Events [CTCAE]) for ubamatamab monotherapyTime frame: Up to 2 years
  10. Number of participants with laboratory abnormalities (grade 3 or higher per CTCAE) for ubamatamab with cemiplimabTime frame: Up to 2 years
  11. Concentration of ubamatamab in serum over time for ubamatamab monotherapyTime frame: Up to 2 years
  12. Concentration of ubamatamab in serum over time for ubamatamab with cemiplimabTime frame: Up to 2 years
  13. Objective response rate (ORR) defined by Response Evaluation Criteria in Solid Tumors (RECIST 1.1) for ubamatamab monotherapyTime frame: Up to 2 years
  14. ORR defined by RECIST 1.1 for ubamatamab with cemiplimabTime frame: Up to 2 years

Locations

54 sites in 10 countries. Site status is shown where the registry gives one.

  • University of Alabama_6th Ave

    Birmingham, Alabama · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Dana Farber / Harvard Cancer Center

    Boston, Massachusetts · Recruiting

  • Mayo Clinic - Rochester

    Rochester, Minnesota · Recruiting

  • Roswell Park Cancer Institute

    Buffalo, New York · Withdrawn

  • Columbia University Medical Center

    New York, New York · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • The Ohio State University Wexner Medical Center

    Columbus, Ohio · Recruiting

  • Stephenson Cancer Center

    Oklahoma City, Oklahoma · Recruiting

  • Sarah Cannon Research Institute

    Nashville, Tennessee · Completed

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Virginia Commonwealth University

    Richmond, Virginia · Recruiting

  • Peter MacCallum Cancer Center

    Melbourne, Australia · Completed

  • Prince of Wales Hospital

    Randwick, New South Wales, Australia · Completed

  • Universitair Ziekenhuis Antwerpen

    Edegem, Antwerp, Belgium · Recruiting

  • Grand Hopital de Charleroi

    Charleroi, Hainaut, Belgium · Recruiting

  • UZLeuven

    Leuven, Vlaams-Brabant, Belgium · Recruiting

  • Centre Leon Berard

    Lyon, France · Recruiting

  • Hopital Lyon Sud

    Pierre-Bénite, Auvergne-Rhône, France · Recruiting

  • Centre Georges Francois Leclerc

    Dijon, Bourgogne-Franche-Comté, France · Recruiting

  • Institut Gustave Roussy

    Villejuif, Île-de-France Region, France · Recruiting

  • Institut Bergonie

    Bordeaux, New Aquitaine, France · Recruiting

  • Centre Francois Baclesse (CFB)

    Caen, Normandy, France · Recruiting

  • Centre Antoine Lacassagne

    Nice, Provence Alpes Cote dAzur, France · Recruiting

  • Rambam Health Care Campus

    Haifa, Israel · Recruiting

  • Sharet Institute of Oncology

    Jerusalem, Israel · Recruiting

  • Sheba Medical Center

    Tel HaShomer, Israel · Recruiting

  • Humanitas S. Pio X

    Milan, Italy · Recruiting

  • Istituto Europeo di Oncologia

    Milan, Italy · Recruiting

  • Instituto Nazionale Tumori- Fondazione Pascale

    Naples, Italy · Recruiting

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS

    Rome, Lazio, Italy · Recruiting

  • University Medical Center Groningen

    Groningen, Netherlands · Recruiting

  • Radboudumc

    Nijmegen, Gelderland, Netherlands · Recruiting

  • Erasmus MC

    Rotterdam, South Holland, Netherlands · Recruiting

  • Yonsei University Health System

    Seoul, South Korea · Recruiting

  • Asan Medical Center, Univ. of Ulsan

    Seoul, South Korea · Recruiting

  • Samsung Medical Center

    Seoul, South Korea · Recruiting

  • Korea University Guro Hospital

    Seoul, South Korea · Recruiting

  • Seoul National University Hospital

    Seoul, South Korea · Recruiting

  • Institut Catala dOncologia Badalona

    Badalona, Spain · Recruiting

Showing 40 of 54 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.